[go: up one dir, main page]

WO2011053565A3 - Compositions and methods for detecting a tauopathy - Google Patents

Compositions and methods for detecting a tauopathy Download PDF

Info

Publication number
WO2011053565A3
WO2011053565A3 PCT/US2010/054026 US2010054026W WO2011053565A3 WO 2011053565 A3 WO2011053565 A3 WO 2011053565A3 US 2010054026 W US2010054026 W US 2010054026W WO 2011053565 A3 WO2011053565 A3 WO 2011053565A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tauopathy
detecting
compositions
subject
Prior art date
Application number
PCT/US2010/054026
Other languages
French (fr)
Other versions
WO2011053565A2 (en
Inventor
Efthimios Skoulakis
Aikaterini Papanikolopoulou
Original Assignee
Biomedical Sciences Research Centre "Alexander Fleming"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Sciences Research Centre "Alexander Fleming" filed Critical Biomedical Sciences Research Centre "Alexander Fleming"
Publication of WO2011053565A2 publication Critical patent/WO2011053565A2/en
Publication of WO2011053565A3 publication Critical patent/WO2011053565A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides antibodies that specifically bind human tau proteins and compositions containing the antibodies. Further provided are methods for obtaining the antibody, methods for detecting a tauopathy in a subject and methods for detecting an agent for treating a tauopathy in a subject.
PCT/US2010/054026 2009-10-29 2010-10-26 Compositions and methods for detecting a tauopathy WO2011053565A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25613509P 2009-10-29 2009-10-29
US61/256,135 2009-10-29

Publications (2)

Publication Number Publication Date
WO2011053565A2 WO2011053565A2 (en) 2011-05-05
WO2011053565A3 true WO2011053565A3 (en) 2011-09-09

Family

ID=43922961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/054026 WO2011053565A2 (en) 2009-10-29 2010-10-26 Compositions and methods for detecting a tauopathy

Country Status (1)

Country Link
WO (1) WO2011053565A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012049570A1 (en) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Human anti-tau antibodies
UA115657C2 (en) * 2011-09-19 2017-12-11 Аксон Ньюросайєнс Сє Isolated antibody that binds to one or more epitopes SAU, a pharmaceutical composition that contains it, METHOD OF TREATMENT AND DIAGNOSIS WAY BASED Alzheimer isolated antibody
SG11201504822VA (en) 2012-12-21 2015-07-30 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
KR102313513B1 (en) 2013-03-13 2021-10-15 프로테나 바이오사이언시즈 리미티드 Tau immunotherapy
LT3083680T (en) 2013-12-20 2020-04-10 F. Hoffmann-La Roche Ag HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
DK3452507T3 (en) 2016-05-02 2022-11-14 Prothena Biosciences Ltd TAU IMMUNOTHERAPY
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
AU2018263935B2 (en) 2017-05-02 2024-09-26 Prothena Biosciences Limited Antibodies recognizing tau
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
CN111521817B (en) * 2020-04-24 2022-03-01 首都医科大学附属北京胸科医院 Method for identifying protein phosphorylation sites
CN119529083A (en) * 2024-12-11 2025-02-28 南京川博生物技术有限公司 Anti-human phosphorylated Tau181 rabbit monoclonal antibody, anti-human phosphorylated Tau217 rabbit monoclonal antibody, preparation method and combined detection application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6121003A (en) * 1994-07-29 2000-09-19 Innogentics N.V. Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
US6500674B1 (en) * 1993-12-21 2002-12-31 Innogenetics N.V. Method for the diagnosis of brain/neurological disease using monoclonal antibodies specific for PHF-tau, hybridomas secreting them, and antigen recognition by these antibodies and their applications
US20030143760A1 (en) * 1992-12-14 2003-07-31 Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US20060008853A1 (en) * 1991-10-25 2006-01-12 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau and method of detecting the same
US20070134724A1 (en) * 2005-08-04 2007-06-14 Peter Davies Phosphorylation of tau by abl

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008853A1 (en) * 1991-10-25 2006-01-12 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau and method of detecting the same
US20030143760A1 (en) * 1992-12-14 2003-07-31 Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US6500674B1 (en) * 1993-12-21 2002-12-31 Innogenetics N.V. Method for the diagnosis of brain/neurological disease using monoclonal antibodies specific for PHF-tau, hybridomas secreting them, and antigen recognition by these antibodies and their applications
US6121003A (en) * 1994-07-29 2000-09-19 Innogentics N.V. Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
US20070134724A1 (en) * 2005-08-04 2007-06-14 Peter Davies Phosphorylation of tau by abl

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REYNOLDS ET AL.: "Phosphorylation Sites on Tau Identified by Nanoelectrospray Mass Spectrometry: Differences In Vitro Between the Mitogen-Activated Protein Kinases ERK2, c-Jun N-Terminal Kinase and P38, and Glycogen Synthase Kanase-3beta", THE JOURNAL OF NEUROCHEMISTRY, vol. 72, no. 4, 2000, pages 1587 - 1595 *

Also Published As

Publication number Publication date
WO2011053565A2 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
WO2011053565A3 (en) Compositions and methods for detecting a tauopathy
WO2011047087A3 (en) Protein detection via nanoreporters
WO2010145792A8 (en) Bispecific antigen binding proteins
IL204615A0 (en) Human antibodies that bind mesothelin, and uses thereof
BRPI0923199A2 (en) methods and compositions for detecting complement-fixing antibodies.
AP2787A (en) Methods, immunoassays and devices for detection ofanti-lipoidal antibodies
WO2014059442A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
PL2328616T3 (en) Compositions and methods for antibodies against complement protein c5
NO20083397L (en) Anti-EphB4 antibodies and methods for their use
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
WO2009070243A3 (en) Wise binding antibodies and epitopes
IL219653A0 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
ZA201108922B (en) Bispecific,tetravalent antigen binding proteins
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2009140039A3 (en) Synthetic antibodies
IL187459A0 (en) Anti - mcp-1 antibodies, compositions, methods and uses
WO2010136483A3 (en) Antigen-binding proteins
WO2008143708A3 (en) Methods and materials related to anti-amyloid antibodies
WO2010121093A3 (en) Humanized antibody compositions and methods for binding lysophosphatidic acid
WO2013009521A3 (en) Methods and compositions for treating asthma using anti-il-13 antibodies
WO2007127506A3 (en) Anti-ephrinb2 antibodies and methods using same
WO2010009856A3 (en) Goodpasture antigen binding protein and its detection
WO2010079510A3 (en) Anti-rhd monoclonal antibodies
IL208188A0 (en) Compositions comprising antibodies or antibody fragments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10827375

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10827375

Country of ref document: EP

Kind code of ref document: A2